Effects of Continuous Oral Intake of DR.ERGO ® Ergothioneine Capsules on Skin Status: A Randomized, Double-Blind, Placebo-Controlled Trial
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Ergothioneine (ergothioneine) is a naturally occurring antioxidant with emerging evidence supporting its role in cellular protection and anti-aging. However, clinical data on its cosmetic benefits remain limited.
Objective
To evaluate the effects of daily oral supplementation with DR.ERGO ® ergothioneine capsules on skin condition in healthy women reporting signs of skin aging.
Methods
In this 8-week, randomized, double-blind, placebo-controlled trial, 66 women aged 35–59 years were assigned to receive either DR.ERGO ® ergothioneine (30 mg/day) or placebo. Skin parameters including melanin index, erythema index, glossiness, elasticity (R2, R5, R7), spot count, wrinkle count were evaluated at baseline, 4 weeks, and 8 weeks.
Results
Compared to placebo, the DR.ERGO ® ergothioneine group showed significantly greater improvements in melanin and erythema reduction, skin glossiness, elasticity, and wrinkle and spot reduction (all p < 0.01). No adverse events were reported.
Conclusion
Continuous oral intake of DR.ERGO ® ergothioneine significantly improved skin aging parameters, with excellent safety and tolerability. These findings suggest DR.ERGO ® ergothioneine may serve as an effective oral anti-aging agent.
